文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

环磷酰胺诱导骨髓产生更高数量的前体树突状细胞,这些细胞能够在体内对 T 细胞进行功能性抗原呈递。

Cyclophosphamide induces bone marrow to yield higher numbers of precursor dendritic cells in vitro capable of functional antigen presentation to T cells in vivo.

机构信息

Surgery Department and Hollings Cancer Center, Medical University of South Carolina, Charleston, 29425, USA.

出版信息

Cell Immunol. 2010;261(2):134-43. doi: 10.1016/j.cellimm.2009.11.011. Epub 2009 Dec 5.


DOI:10.1016/j.cellimm.2009.11.011
PMID:20036354
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2821961/
Abstract

We have shown recently that cyclophosphamide (CTX) treatment induced a marked increase in the numbers of immature dendritic cells (DCs) in blood, coinciding with enhanced antigen-specific responses of the adoptively transferred CD8(+) T cells. Because this DC expansion was preceded by DC proliferation in bone marrow (BM), we tested whether BM post CTX treatment can generate higher numbers of functional DCs. BM was harvested three days after treatment of C57BL/6 mice with PBS or CTX and cultured with GM-CSF/IL-4 in vitro. Compared with control, BM from CTX-treated mice showed faster generation and yielded higher numbers of DCs with superior activation in response to toll-like receptor (TLR) agonists. Vaccination with peptide-pulsed DCs generated from BM from CTX-treated mice induced comparable adjuvant effects to those induced by control DCs. Taken together, post CTX BM harbors higher numbers of DC precursors capable of differentiating into functional DCs, which be targeted to create host microenvironment riches in activated DCs upon treatment with TLR agonists.

摘要

我们最近已经表明,环磷酰胺(CTX)治疗会导致血液中未成熟树突状细胞(DC)数量明显增加,同时增强了过继转移的 CD8(+) T 细胞的抗原特异性反应。由于这种 DC 扩增之前在骨髓(BM)中发生了 DC 增殖,我们测试了 CTX 治疗后 BM 是否可以产生更多数量的功能性 DC。在 PBS 或 CTX 处理 C57BL/6 小鼠 3 天后收获 BM,并在 GM-CSF/IL-4 体外培养。与对照组相比,CTX 处理组的 BM 显示出更快的生成速度,并产生了更多数量的 DC,对 Toll 样受体(TLR)激动剂的反应更优。用从 CTX 处理的 BM 产生的肽脉冲 DC 进行疫苗接种可诱导与对照 DC 诱导的相似的佐剂效应。总之,CTX 后 BM 含有更多的 DC 前体,能够分化为功能性 DC,这些前体可以在 TLR 激动剂治疗时靶向产生富含激活的 DC 的宿主微环境。

相似文献

[1]
Cyclophosphamide induces bone marrow to yield higher numbers of precursor dendritic cells in vitro capable of functional antigen presentation to T cells in vivo.

Cell Immunol. 2009-12-5

[2]
Cyclophosphamide induces dynamic alterations in the host microenvironments resulting in a Flt3 ligand-dependent expansion of dendritic cells.

J Immunol. 2010-2-15

[3]
Minocycline promotes the generation of dendritic cells with regulatory properties.

Oncotarget. 2016-8-16

[4]
Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs.

Blood. 2010-2-12

[5]
Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C).

J Immunol. 2009-2-15

[6]
Lead effects on development and function of bone marrow-derived dendritic cells promote Th2 immune responses.

Toxicol Appl Pharmacol. 2007-7-1

[7]
Cognate interactions between memory T cells and tumor antigen-presenting dendritic cells from bone marrow of breast cancer patients: bidirectional cell stimulation, survival and antitumor activity in vivo.

Int J Cancer. 2003-1-1

[8]
Dendritic cells support hematopoiesis of bone marrow cells.

Transplantation. 2001-9-15

[9]
Functional comparison of spleen dendritic cells and dendritic cells cultured in vitro from bone marrow precursors.

Blood. 1996-11-1

[10]
Comparative analysis of murine marrow-derived dendritic cells generated by Flt3L or GM-CSF/IL-4 and matured with immune stimulatory agents on the in vivo induction of antileukemia responses.

Blood. 2002-12-1

引用本文的文献

[1]
Lymphodepletion chemotherapy in chimeric antigen receptor-engineered T (CAR-T) cell therapy in lymphoma.

Bone Marrow Transplant. 2025-5

[2]
The future of metronomic chemotherapy: experimental and computational approaches of drug repurposing.

Pharmacol Rep. 2025-2

[3]
Metronomic chemotherapy: bridging theory to clinical application in canine and feline oncology.

Front Vet Sci. 2024-6-6

[4]
The Role of Toll-like Receptor Agonists and Their Nanomedicines for Tumor Immunotherapy.

Pharmaceutics. 2022-6-10

[5]
: A Potential New Treatment Option for Human Breast Cancer and Its Validation in a Clinical Setting.

Breast Cancer (Auckl). 2022-2-14

[6]
Theoretical premises of a "three in one" therapeutic approach to treat immunogenic and nonimmunogenic cancers: a narrative review.

Transl Cancer Res. 2021-11

[7]
Efficacy of the new therapeutic approach in curing malignant neoplasms on the model of human glioblastoma.

Cancer Biol Med. 2021-7-14

[8]
Leveraging Endogenous Dendritic Cells to Enhance the Therapeutic Efficacy of Adoptive T-Cell Therapy and Checkpoint Blockade.

Front Immunol. 2020

[9]
High-Dose Cyclophosphamide Administration Orchestrates Phenotypic and Functional Alterations of Immature Dendritic Cells and Regulates Th Cell Polarization.

Front Pharmacol. 2020-5-25

[10]
Metronomic Chemotherapy: A Systematic Review of the Literature and Clinical Experience.

J Oncol. 2019-3-20

本文引用的文献

[1]
Cyclophosphamide induces dynamic alterations in the host microenvironments resulting in a Flt3 ligand-dependent expansion of dendritic cells.

J Immunol. 2010-2-15

[2]
Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination.

Cancer Immunol Immunother. 2010-1

[3]
Radiotherapy combined with intratumoral dendritic cell vaccination enhances the therapeutic efficacy of adoptive T-cell transfer.

J Immunother. 2009

[4]
High-dose cyclophosphamide-mediated anti-tumor effects by the superior expansion of CD44(high) cells after their selective depletion.

Immunobiology. 2009-5-22

[5]
Adoptive T cell therapy of cancer.

Curr Opin Immunol. 2009-4

[6]
Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C).

J Immunol. 2009-2-15

[7]
FOCUS on FOCIS: combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer.

Clin Immunol. 2009-4

[8]
Morphology of the bone marrow, spleen and liver during hematopoietic cell mobilization with cyclophosphamide in mice.

Folia Histochem Cytobiol. 2008

[9]
The TLR3 agonist poly(I:C) targets CD8+ T cells and augments their antigen-specific responses upon their adoptive transfer into naïve recipient mice.

Vaccine. 2009-1-22

[10]
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.

J Clin Oncol. 2008-11-10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索